219 related articles for article (PubMed ID: 38569225)
1. Advances in molecular targeted drugs in combination with CAR-T cell therapy for hematologic malignancies.
Huang Y; Qin Y; He Y; Qiu D; Zheng Y; Wei J; Zhang L; Yang DH; Li Y
Drug Resist Updat; 2024 May; 74():101082. PubMed ID: 38569225
[TBL] [Abstract][Full Text] [Related]
2. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
3. Advances in CAR-T-cell therapy in T-cell malignancies.
Zheng R; Zhu X; Xiao Y
J Hematol Oncol; 2024 Jun; 17(1):49. PubMed ID: 38915099
[TBL] [Abstract][Full Text] [Related]
4. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
Lindo L; Wilkinson LH; Hay KA
Front Immunol; 2020; 11():618387. PubMed ID: 33643299
[TBL] [Abstract][Full Text] [Related]
5. T Cell Exhaustion and CAR-T Immunotherapy in Hematological Malignancies.
Tang L; Zhang Y; Hu Y; Mei H
Biomed Res Int; 2021; 2021():6616391. PubMed ID: 33728333
[TBL] [Abstract][Full Text] [Related]
6. Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.
Dreyzin A; Rankin AW; Luciani K; Gavrilova T; Shah NN
Expert Rev Clin Immunol; 2024 Jul; 20(7):745-763. PubMed ID: 38739466
[TBL] [Abstract][Full Text] [Related]
7. Advances in research on factors affecting chimeric antigen receptor T-cell efficacy.
Zhou D; Zhu X; Xiao Y
Cancer Med; 2024 Jun; 13(11):e7375. PubMed ID: 38864474
[TBL] [Abstract][Full Text] [Related]
8. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
9. CAR-T therapy and targeted treatments: Emerging combination strategies in solid tumors.
Liu J; Jiao X; Ma D; Fang Y; Gao Q
Med; 2024 Jun; 5(6):530-549. PubMed ID: 38547867
[TBL] [Abstract][Full Text] [Related]
10. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
11. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
12. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
Ti D; Niu Y; Wu Z; Fu X; Han W
Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
[TBL] [Abstract][Full Text] [Related]
13. How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.
Hill JA; Seo SK
Blood; 2020 Aug; 136(8):925-935. PubMed ID: 32582924
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of CAR T cell in malignancies: A scoping review.
Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
[TBL] [Abstract][Full Text] [Related]
15. CAR T-Cell Therapy in Hematologic Malignancies: A Voyage in Progress.
Holstein SA; Lunning MA
Clin Pharmacol Ther; 2020 Jan; 107(1):112-122. PubMed ID: 31622496
[TBL] [Abstract][Full Text] [Related]
16. Novel technologies for improving the safety and efficacy of CAR-T cell therapy.
Ohta K; Sakoda Y; Tamada K
Int J Hematol; 2023 May; 117(5):647-651. PubMed ID: 36309630
[TBL] [Abstract][Full Text] [Related]
17. Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31658644
[TBL] [Abstract][Full Text] [Related]
18. Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies.
Zhang ZZ; Wang T; Wang XF; Zhang YQ; Song SX; Ma CQ
Pharmacol Res; 2022 Jan; 175():106036. PubMed ID: 34920118
[TBL] [Abstract][Full Text] [Related]
19. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
Front Immunol; 2021; 12():638639. PubMed ID: 34177890
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of Immune Checkpoint Blockade into Chimeric Antigen Receptor T Cells (CAR-Ts): Combination or Built-In CAR-T.
Yoon DH; Osborn MJ; Tolar J; Kim CJ
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]